You just read:

Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

News provided by

Helsinn Healthcare SA

16 May, 2013, 07:00 BST